Edgewise Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 06, 2025, EWTX reported earnings of -0.39 USD per share (EPS) for Q3 25, beating the estimate of -0.40 USD, resulting in a 3.82% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.61% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analysts forecast an EPS of -0.44 USD, with revenue projected to reach -- USD, implying an increase of 12.82% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Oncology, Inc. Common Stock
Report Date
Dec 23, 2025 For Q4 25
Estimate
-$0.12
Actual
-$0.06
Surprise
+50.98%
FAQ
What were Edgewise Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Edgewise Therapeutics, Inc. Common Stock reported EPS of -$0.39, beating estimates by 3.82%, and revenue of $0.00, 0% as expectations.
How did the market react to Edgewise Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -1.61%, changed from $17.37 before the earnings release to $17.09 the day after.
When is Edgewise Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 02, 2026.
What are the forecasts for Edgewise Therapeutics, Inc. Common Stock's next earnings report?
Based on 14
analysts, Edgewise Therapeutics, Inc. Common Stock is expected to report EPS of -$0.44 and revenue of -- for Q4 2025.